Most Popular - Thursday morning, Israeli financial newspaper, Calcalist is reporting that Teva Pharmaceuticals (NASDAQ:TEVA) and AstraZeneca (NYSE:AZN) are leading candidates among other large drug companies interested in … Continue Reading
Read NowMost Popular - Pharmacyclics warned in its 3Q earnings release that employees might sell market-moving amounts of shares on Wednesday as they exercised options. As we expected, shares … Continue Reading
Read NowLong Ideas - Earnings for Amarin Corp. (NASDAQ:AMRN) were primarily focused on the company’s strategy for the launch of Vascepa, as well as the FDA’s decision on whether … Continue Reading
Read NowLong Ideas - Esbriet (perfenidone) sales in Europe have begun to pick up according to InterMune’s (NASDAQ:ITMN) third quarter results, driven largely (91%) by sales in Germany where … Continue Reading
Read NowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) updated investors Thursday morning on both its Zerenex development program and its 3Q financials, reiterating that pivotal Phase 3 data for the … Continue Reading
Read NowMost Popular - Gilead paid a lot of money – $11B to be exact – to acquire Pharmasset back in 2011. Was it worth it? Propthink dug in … Continue Reading
Read NowMost Popular - Hepatitis C drug developers have been swiftly moving towards interferon-free, oral regimens, and while Vertex’s (NASDAQ:VRTX) Incivek was briefly the lead treatment in the field, … Continue Reading
Read Now